Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.